MedTrace Logo

FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

NCT01470664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2021-06-25

No results posted yet for this study

Summary

This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute adenoviral conjunctivitis.

Conditions

  • Acute Adenoviral Conjunctivitis

Interventions

DRUG

FST-100

0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)

DRUG

FST-100 (Component #1)

0.6% PVP-Iodine ophthalmic solution alone

DRUG

FST-100 Vehicle

FST-100 Vehicle

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-17
Primary Completion
2014-05-23
Completion
2014-05-23

Countries

  • United States
  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470664 on ClinicalTrials.gov